NUREXUS
Journal of MedVerse Research & Practice
nurexus.com

Managing Short Bowel Syndrome in Neonates and Young Infants: A Clinical Overview

Dr. Shrisha[1], Dr. Surya[2]
Postgraduate, Assistant Professor
Department of Pediatrics, SRM Medical College Hospital, Trichy
Email: Shrisha789@gmail.com

Submission Date: 24.02.2025	Accepted Date: 22.03.2025	Published Date: 31.03.2025
DOI: 10.65188/nurexus.1016		

Abstract

Short bowel syndrome (SBS) is a significant condition in neonates and infants, resulting from extensive bowel resection due to congenital or acquired causes. This disorder leads to malabsorption, posing challenges in nutrient absorption and overall growth. Advances in neonatal care and surgical techniques have improved survival rates, but long-term management remains complex. This review explores the etiologies, clinical manifestations, diagnostic approaches, and treatment strategies for SBS in early life. Current therapeutic approaches include parenteral nutrition, enteral feeding advancements, surgical interventions, and emerging regenerative therapies. A multidisciplinary approach is crucial for optimizing outcomes, enhancing quality of life, and reducing dependency on parenteral nutrition. Further research is necessary to develop innovative treatments that support intestinal adaptation and improve long-term prognosis.

Keywords: Short Bowel Syndrome, Neonates, Infants, Malabsorption, Intestinal Adaptation, Parenteral Nutrition

Introduction

Short bowel syndrome (SBS) is a rare yet serious condition affecting neonates and infants, primarily resulting from congenital anomalies or surgical resection due to necrotizing enterocolitis, intestinal atresia, or midgut volvulus [1]. This disorder is characterized by significant malabsorption, leading to nutritional deficiencies, dehydration, and failure to thrive [2]. The severity of SBS depends on the remaining bowel length and its ability to adapt over time [3].

Advancements in neonatal intensive care and surgical interventions have significantly improved the survival of infants with SBS. However, managing this condition remains challenging due to the long-term dependence on parenteral nutrition (PN), which carries risks of liver dysfunction, infections, and metabolic complications [4]. The goal of SBS management is to promote intestinal adaptation, enabling a gradual transition to enteral nutrition while minimizing complications [5].

Several therapeutic strategies have been explored to enhance intestinal adaptation, including optimized nutritional support, pharmacological agents, and surgical approaches such as bowel lengthening procedures [6]. Emerging regenerative therapies, including tissue engineering and stem cell applications, hold promise for improving outcomes in affected infants [7]. This review aims to provide a comprehensive overview of the pathophysiology, diagnostic approaches, and evolving treatment modalities for SBS in neonates and

early infancy. Understanding the latest advancements in management strategies is crucial for optimizing care and improving long-term prognosis [8].

Definition of Short Bowel Syndrome

Short bowel syndrome (SBS) is a disorder characterized by the loss or malfunction of a significant portion of the small intestine, resulting in severe malabsorption and the inability to sustain adequate nutrition through oral intake alone [9]. The severity of SBS is influenced by multiple factors, including the length of the residual bowel, the specific intestinal segments remaining, and the body's capacity for intestinal adaptation [10]. Patients with SBS often require intensive medical support, particularly specialized nutritional strategies, to compensate for reduced absorptive capacity and to prevent malnutrition-related complications [11].

Cause

The underlying causes of SBS in neonates and infants can be classified into congenital and acquired conditions. Congenital causes include intestinal atresia, gastroschisis, and congenital short bowel syndrome, which result in an underdeveloped or abnormally short intestine at birth [12]. Acquired causes, on the other hand, involve the necessity of extensive bowel resection due to severe conditions such as necrotizing enterocolitis, midgut volvulus, intestinal ischemia, and traumatic bowel injury [13]. The etiology of SBS plays a pivotal role in determining prognosis, influencing the potential for intestinal adaptation and long-term clinical outcomes [14].

Pathophysiology

SBS disrupts normal gastrointestinal function by drastically reducing the intestinal surface area available for digestion and nutrient absorption [15]. The degree of malabsorption depends on the extent and location of the remaining intestine, as different intestinal segments perform distinct roles in nutrient absorption. The duodenum and jejunum are primarily responsible for absorbing carbohydrates, proteins, and fats, while the ileum is essential for vitamin B12 absorption and bile acid reuptake [16].

Following intestinal resection, the remaining bowel initiates a compensatory adaptive response aimed at increasing its absorptive efficiency. This adaptive process is marked by structural and functional changes, including villous hyperplasia, increased crypt cell proliferation, and the upregulation of nutrient transporter proteins, all of which contribute to improved absorption [17]. Several factors modulate the extent of intestinal adaptation, including the presence of the ileocecal valve, the remaining length of the small intestine, and the role of the colon in enhancing digestion and fluid retention [18].

Predictors of Enteral Autonomy

Enteral autonomy is defined as the ability of an individual with SBS to maintain adequate nutritional intake through enteral feeding alone, without the need for long-term parenteral nutrition [19]. Several key determinants influence the likelihood of achieving enteral independence, including the residual bowel length, the functionality of the ileocecal valve, and the extent of colonic involvement in nutrient and fluid absorption [20].

Early initiation and gradual progression of enteral feeding are crucial for stimulating intestinal adaptation, improving absorptive efficiency, and facilitating enteral autonomy [21]. Emerging pharmacological therapies, such as glucagon-like peptide-2 (GLP-2) analogs, have demonstrated efficacy in enhancing intestinal adaptation by promoting mucosal growth and increasing nutrient absorption capacity [22]. Moreover, a comprehensive multidisciplinary approach incorporating optimized nutrition plans, surgical techniques, and novel therapeutic interventions has significantly improved the likelihood of weaning patients from parenteral nutrition, thereby reducing associated complications and enhancing overall quality

of life [23].

Complications

Short bowel syndrome (SBS) is associated with a wide range of complications that significantly impact patient outcomes and quality of life. These complications arise due to severe malabsorption, intestinal dysmotility, and prolonged dependence on parenteral nutrition (PN) [24]. One of the most common complications is intestinal failure-associated liver disease (IFALD), which results from prolonged PN use, leading to cholestasis, hepatic fibrosis, and potential liver failure [25]. Catheter-related bloodstream infections (CRBSIs) pose another serious risk, as the long-term requirement for central venous catheters increases susceptibility to infections, sepsis, and thrombotic complications [26].

Nutritional deficiencies are another major concern in SBS patients, as impaired absorption leads to deficits in essential macronutrients and micronutrients, including fat-soluble vitamins (A, D, E, and K), iron, zinc, and calcium, which can cause growth failure, osteoporosis, and immune dysfunction [27]. Additionally, fluid and electrolyte imbalances, particularly sodium and potassium losses, contribute to chronic dehydration and metabolic derangements, necessitating careful monitoring and supplementation [28]. Patients with SBS may also experience small intestinal bacterial overgrowth (SIBO), which exacerbates malabsorption by disrupting gut microbiota and increasing the risk of diarrhea, bloating, and malnutrition [29]. Furthermore, those who undergo bowel lengthening procedures are at risk of developing anastomotic strictures, intestinal obstructions, and recurrent episodes of bowel dilatation [30].

Management

The management of SBS requires a multidisciplinary approach aimed at optimizing intestinal adaptation, minimizing complications, and improving long-term nutritional independence [31]. The cornerstone of treatment is nutritional support, which initially relies on PN to meet caloric and fluid requirements while gradually transitioning to enteral feeding to stimulate intestinal adaptation and promote functional recovery [32].

Enteral nutrition plays a critical role in SBS management by enhancing gut motility, promoting mucosal growth, and reducing dependency on PN. The introduction of trophic feeds at an early stage, even in minimal amounts, has been shown to facilitate intestinal adaptation and improve long-term outcomes [33]. Specialized diets, including elemental and semi-elemental formulas, are often used to enhance nutrient absorption in patients with compromised digestive capacity [34].

Pharmacological interventions have emerged as key components in SBS management, particularly glucagon-like peptide-2 (GLP-2) analogs such as teduglutide, which have demonstrated effectiveness in promoting intestinal growth, increasing nutrient absorption, and reducing the need for PN [35]. Other supportive medications include anti-motility agents like loperamide and proton pump inhibitors to manage diarrhea and acid-related complications, respectively [36].

Surgical approaches are considered in cases where conservative management fails to achieve enteral autonomy. Intestinal lengthening procedures, including the Bianchi and serial transverse enteroplasty (STEP) techniques, aim to increase bowel surface area and improve absorptive function [37]. In severe cases, intestinal transplantation may be considered for patients who develop irreversible complications from PN, such as life-threatening liver disease or recurrent sepsis [38].

Emerging therapies in regenerative medicine, including tissue engineering and stem cell therapy, hold promise for revolutionizing SBS treatment by enhancing mucosal regeneration and restoring functional

intestinal tissue [39]. Advances in microbiome research are also paving the way for novel therapeutic strategies, such as fecal microbiota transplantation, to modulate gut flora and improve nutrient absorption [40]. Ultimately, a tailored, patient-centered approach integrating nutritional, pharmacological, and surgical Strategies are crucial for optimizing SBS outcomes and improving survival rates in neonates and infants [41].

Pharmacological Approaches in SBS

Pharmacological interventions have emerged as key components in SBS management, particularly glucagon-like peptide-2 (GLP-2) analogs such as teduglutide, which have demonstrated effectiveness in promoting intestinal growth, increasing nutrient absorption, and reducing the need for PN [35]. Other supportive medications include anti-motility agents like loperamide and proton pump inhibitors to manage diarrhea and acid-related complications, respectively [36].

Prevention and Management of Central Line-Associated Bloodstream Infections (CLABSI):

Given the dependence on long-term PN, SBS patients are highly susceptible to CLABSI, which can lead to sepsis and life-threatening complications. Preventative strategies include strict aseptic techniques during catheter insertion and maintenance, regular monitoring for early signs of infection, ethanol lock therapy, and antibiotic prophylaxis when necessary [37]. The proper education of caregivers and healthcare providers plays a critical role in reducing infection rates and improving patient outcomes [38].

Surgical Considerations in SBS Treatment

Surgical interventions are considered for patients with SBS when conservative measures fail to achieve enteral autonomy. Intestinal lengthening procedures, such as the Bianchi and serial transverse enteroplasty (STEP) techniques, increase the functional surface area of the small intestine, enhancing nutrient absorption [39]. For patients with irreversible complications related to PN, intestinal transplantation remains a viable option, offering improved survival and quality of life [40].

Mucous Fistula Refeeding (MFR) and Stoma Reversal

MFR has emerged as a beneficial technique in neonates and infants with SBS, allowing the use of proximal enteric secretions to enhance intestinal adaptation and promote mucosal growth. This method facilitates the reintroduction of gut nutrients, ultimately aiding in the transition towards full enteral feeding [41]. Stoma reversal, performed when the residual bowel has achieved sufficient adaptation, further supports the restoration of intestinal continuity, improving nutrient absorption and reducing dependence on PN [42].

Prognosis and Long-Term Outcomes:

The prognosis of SBS largely depends on the residual bowel length, underlying etiology, and the success of intestinal adaptation. Advances in medical and surgical management have significantly improved survival rates, with many patients achieving partial or complete enteral autonomy over time. Long-term follow-up is essential to monitor for complications such as nutritional deficiencies, liver dysfunction, and growth impairment [43]. Emerging therapies, including regenerative medicine and gut microbiome modulation, hold promise for further improving outcomes in affected individuals [44,45].

Conclusion

SBS remains a complex and challenging condition requiring a comprehensive, patient-centered approach. Advances in nutritional support, pharmacological interventions, surgical techniques, and emerging therapies have significantly enhanced the management and prognosis of SBS patients. Continued research and multidisciplinary collaboration are crucial in optimizing long-term outcomes and improving the quality of life for individuals affected by this disorder

Conflict of Interest: Nil

Reference

1. Fallon EM, Mitchell PD, Nehra D, Potemkin AK, O'Loughlin AA, Gura KM, et al. Neonates with short bowel syndrome: An optimistic future for parenteral nutrition independence. JAMA Surg. 2014; 149:663–70. Available from: https://doi.org/10.1001/jamasurg.2013.4332
2. Han SM, Knell J, Henry O, Hong CR, Han GY, Staffa SJ, et al. Long-term outcomes and disease burden of neonatal on set short bowel syndrome. J Pediatr Surg. 2020; 55:164-8. Available https://doi.org/10.1016/j.jpedsurg.2019.09.071. from:
3. Modi BP, Langer M, Ching YA, Valim C, Waterford SD, Igle sias J, et al. Improved survival in a multidisciplinary short bowel syndrome program. J Pediatr Surg. 2008; 43:20e4. 4. 5.
4. Modi BP, Galloway DP, Gura K, Nucci A, Plogsted S, Tucker A, et al. ASPEN definitions in pediatric intestinal failure. JPEN J Parenter Enteral Nutr. 2022; 46:42-59. Available from: https://doi.org/10.1002/jpen.2232. Epub 2021 Sep 15. PMID: 34287974.
5. Merritt RJ, Cohran V, Raphael BP, Sentongo T, Volpert D, Warner BW, et al. Nutrition Committee of the North Ameri can Society for Pediatric Gastroenterology, Hepatology and Nutrition. Intestinal rehabilitation programs in the man agement of pediatric intestinal failure and short bowel syn drome. J Pediatr Gastroenterol Nutr. 2017; 65:588-96.
6. Struijs MC, Diamond IR, de Silva N, Wales PW. Establish ing norms for intestinal length in children. J Pediatr Surg. 2009; 44:933-8. Available https://doi.org/10.1016/j.jpedsurg.2009.01.031. 7. from:
7. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intesti nal failure: consensus definitions and overview. Clin Gas troenterol Hepatol. 2006; 4:6-10. Available from: https://doi.org/10.1016/j.cgh.2005.10.002. 8.
8. Batra A, Keys SC, Johnson MJ, Wheeler RA, Beattie RM. Epidemiology, management, and outcome of ultrashort bowel syndrome in infancy. Arch Dis Childhood-Fetal Neo natal Edition. 2017; 102:F551-6.
9. Duro D, Kamin D, Duggan C. Overview of pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2008; 47:S33-6. Available from: https://doi.org/10.1097/MPG.0b013e3181819007.
10. Wales PW, de Silva N, Kim J, Lecce L, To T, Moore A. Neo natal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg. 2004; 39:690-5.
11. Khan FA, Squires RH, Litman HJ, Balint J, Carter BA, Fisher JG, et al. Pediatric Intestinal Failure Consortium Predictors of enteral autonomy in children with intestinal failure: A multicenter cohort study. J Pediatr. 2015; 167:29-34. Available from: https://doi.org/10.1016/j.jpeds.2015.03.040.
12. Peters FB, Bone JN, Van Oerle R, Albersheim S, Casey L, Piper H. The Importance of the ileocecal valve and colon in achieving intestinal independence in infants with short bowel syndrome. J Pediatr Surg. 2022; 57:117-121. Availa ble from: https://doi.org/10.1016/j.jpedsurg.2021.09.028.
13. Engelstad HJ, Danko ME. Short bowel syndrome in an infant. Neoreviews. 2020; 21:e370-e382. Available from: https://doi.org/10.1542/neo.21-6-e370.
14. Bailly-Botuha C, Colomb V, Thioulouse E, Berthe MC, Gar cette K, Dubern B, et al. Plasma citrulline concentration re flects enterocyte mass in children with short bowel syn drome. Pediatr Res. 2009; 65:559-63.
15. Proli F, Faragalli A, Talbotec C, Bucci A, Zemrani B, Char dot C, et al. Variation of plasma citrulline as a predictive factor for weaning off long-term parenteral nutrition in children with neonatal short bowel syndrome. Clin Nutr. 2021; 40:4941-4947. Available from: https://doi.org/10.1016/j.clnu.2021.07.017.
16. Doldi SB. Intestinal adaptation following jejunoileal bypass. Clin Nutr. 1991; 10:138-45.
17. Warner BW. The pathogenesis of resection-associated intes tinal adaptation. Cellular Molecul Gastroenterol Hepatol. 2016; 2:429-38.
18. Tappenden KA. Intestinal adaptation following resection. JPEN J Parenter Enteral Nutr. 2014; 38:23S-31S. Available from: https://doi.org/10.1177/0148607114525210.
19. Piper HG, de Silva NT, Amaral JG, Avitzur Y, Wales PW. Peripherally inserted central catheters for long-term paren teral nutrition in infants with intestinal failure. J Pediatr Gastroenterol Nutr. 2013; 56:578-81. Available from: https://doi.org/10.1097/MPG.0b013e3182801e7b.

20. Khalaf RT, Sokol RJ. New insights into intestinal failure associated liver disease in children. Hepatol. 2020; 71:1486-98. Available from: https://doi.org/10.1002/hep.31152.
21. Gutierrez IM, Kang KH, Calvert CE, Johnson VM, Zurakow ski D, Kamin D, et al. Risk factors for small bowel bacterial overgrowth and diagnostic yield of duodenal aspirates in children with intestinal failure: a retrospective review. J Pe diatr Surg. 2012; 47:1150-4. Available from: https://doi.org/10.1016/j.jpedsurg.2012.03.019.
22. Grace E, Shaw C, Whelan K, Andreyev HJ. Small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013; 38:674-88.
23. Puwanant M, Mo-Suwan L, Patrapinyokul S. Recurrent D lactic acidosis in a child with short bowel syndrome. Asia Pac J Clin Nutr. 2005; 14:195-8.
24. Feng H, Zhang T, Yan W, Lu L, Tao Y, Cai W, et al. Micro nutrient deficiencies in pediatric short bowel syndrome: a 10-year review from an intestinal rehabilitation center in China. Pediatr Surg Int. 2020; 36:1481-7. Available from: https://doi.org/10.1007/s00383-020-04764-3.
25. Duro D, Jaksic T, Duggan C. Multiple micronutrient defi ciencies in a child with short bowel syndrome and normal somatic growth. J Pediatr Gastroenterol Nutr. 2008; 46:461-4.
26. Crealey M, Walsh M, Awadalla S, Murphy JF. Managing newborn ileostomies. Ir Med J. 2014; 107:146-8.
27. Butterworth SA, Lalari V, Dheensaw K. Evaluation of sodi um deficit in infants undergoing intestinal surgery. J Pedi atr Surg. 2014; 49:736–40.
28. Norsa L, Nicastro E, Di Giorgio A, Lacaille F, D'Antiga L. Prevention and treatment of intestinal failure-associated liver disease in children. Nutrients. 2018; 10:664. Available from: https://doi.org/10.3390/nu10060664.
29. Raphael BP, Mitchell PD, Gura KM, Potemkin AK, Squires RH, Puder M, et al. Growth in infants and children with in testinal failure-associated liver disease treated with intra venous fish oil. J Pediatr Gastroenterol Nutr. 2020; 70:261 8. Available from: https://doi.org/10.1097/MPG.0000000000002551.
30. Lacaille F, Gupte G, Colomb V, D'Antiga L, Hartman C, Hojsak I, et al. ESPGHAN Working Group of Intestinal Fail ure and Intestinal Transplantation. Intestinal failure associated liver disease: a position paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Trans plantation. J Pediatr Gastroenterol Nutr. 2015; 60:272-83. Available from: https://doi.org/10.1097/MPG.0000000000000586.
31. Nghiem-Rao TH, Cassidy LD, Polzin EM, Calkins CM, Arca MJ, Goday PS. Risks and benefits of prophylactic cyclic parenteral nutrition in surgical neonates. Nutr Clin Pract. 2013; 28:745-52. Available from: https://doi.org/10.1177/0884533613502813.
32. Olieman JF, Penning C, Ijsselstijn H, Escher JC, Joosten KF, Hulst JM, et al. Enteral nutrition in children with short-bowel syndrome: current evidence and recommenda tions for the clinician. J Am Diet Assoc. 2010; 110:420-6. Available from: https://doi.org/10.1016/j.jada.2009.12.001.
33. Ekingen G, Ceran C, Guvenc BH, Tuzlaci A, Kahraman H. Early enteral feeding in newborn surgical patients. Nutri tion. 2005; 21:142-6. Available from: https://doi.org/10.1016/j.nut.2004.10.003.
34. Teresa C, Valerio N, Laura S, Salvatore C, Francesca L, Alessandra L, et al. Enteral nutrition in pediatric intestinal failure: does initial feeding impact on intestinal adapta tion?, Expert Rev Gastroenterol Hepatol. 2017; 11:741-8, Available from: https://doi.org/10.1080/17474124.2017.1335196.
35. Bhatia J, Gates A, Parish A. Medical management of short gut syndrome. J Perinatol. 2010; 30:S2-5.
36. Diamanti A, Fiocchi AG, Capriati T, Panetta F, Pucci N, Bellucci F, et al. Cow's milk allergy and neonatal short bowel syndrome: comorbidity or true association? Eur J Clin Nutr. 2015; 69:102-6. Available from: https://doi.org/10.1038/ejcn.2014.156.
37. Oly F, Dray X, Corcos O, Barbot L, Kapel N, Messing B. Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterol. 2009; 136:824-31. Available from: https://doi.org/10.1053/j.gastro.2008.10.084.
38. Kumpf VJ. Pharmacologic management of diarrhea in pa tients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014; 38:38S-44S. Available from: https://doi.org/10.1177/0148607113520618.
39. Raphael BP, Nurko S, Jiang H, Hart K, Kamin DS, Jaksic T, et al. Cisapride improves enteral tolerance in pediatric short-bowel syndrome with dysmotility. J Pediatr Gastroen terol Nutr. 2011; 52:590-4. Available from: https://doi.org/10.1097/MPG.0b013e3181fe2d7a.

40. Kouti V, Papazoglou L, Flaskos J, Angelopoulou K, Karkavelas G, Rallis T. Ursodeoxycholic acid promotes in testinal adaptation in a cat model of short bowel syndrome. Fundam Clin Pharmacol. 2011; 25:734-42. Available from: https://doi.org/10.1111/j.1472-8206.2010.00901.x.
41. Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH. Ursodeoxycholic acid (UDCA) therapy in very-low birth-weight infants with parenteral nutrition-associated 1472-7859
42. Frongia G, Kessler M, Weih S, Nickkholgh A, Mehrabi A, Holland-Cunz S. Comparison of LILT and STEP procedures in children with short bowel syndrome- a systematic review of the literature. J Pediatr Surg. 2013; 48:1794-805. Available from: https://doi.org/10.1016/j.jpedsurg.2013.05.018.
43. Bhat S, Cameron NR, Sharma P, Bissett IP, O'Grady G. Chyme recycling in the management of small bowel double enterostomy in pediatric and neonatal populations: A systematic review. Clin Nutr ESPEN. 2020; 37:1-8. Available from: https://doi.org/10.1016/j.clnesp.2020.03.013.
44. Ghattaura H, Borooah M, Jester I. A review on safety and outcomes of mucous fistula refeeding in neonates. Eur J Pediatr Surg. 2022; 32:146-52. Available from: https://doi.org/10.1055/s-0040-1718751.
45. Sparks EA, Khan FA, Fisher JG, Fullerton BS, Hall A, Raphael BP, et al. Necrotizing enterocolitis is associated with earlier achievement of enteral autonomy in children with short bowel syndrome. J Pediatr Surg. 2016; 51:92-5. Available from: https://doi.org/10.1016/j.jpedsurg.2015.10.023.